|
1
|
Sellers TA: Genetic factors in the
pathogenesis of breast cancer: their role and relative importance.
J Nutr. 27(5 Suppl): 929S–932S. 1997.
|
|
2
|
Psaila B and Lyden D: The metastatic
niche: adapting the foreign soil. Nat Rev Cancer. 9:285–293.
2009.
|
|
3
|
Yarden Y: The EGFR family and its ligands
in human cancer. signalling mechanisms and therapeutic
opportunities. Eur J Cancer. 37(Suppl 4): S3–S8. 2001.
|
|
4
|
Ghosh R, Narasanna A, Wang SE, et al:
Trastuzumab has preferential activity against breast cancers driven
by HER2 homodimers. Cancer Res. 71:1871–1882. 2011.
|
|
5
|
Kulbe H, Levinson NR, Balkwill F and
Wilson JL: The chemokine network in cancer - much more than
directing cell movement. Int J Dev Biol. 48:489–496. 2004.
|
|
6
|
Kuhlmann CR, Schaefer CA, Reinhold L,
Tillmanns H and Erdogan A: Signalling mechanisms of SDF-induced
endothelial cell proliferation and migration. Biochem Biophys Res
Commun. 335:1107–1114. 2005.
|
|
7
|
Wang J, Wang J, Sun Y, et al: Diverse
signaling pathways through the SDF-1/CXCR4 chemokine axis in
prostate cancer cell lines leads to altered patterns of cytokine
secretion and angiogenesis. Cell Signal. 17:1578–1592. 2005.
|
|
8
|
Chu H, Zhou H, Liu Y, et al: Functional
expression of CXC chemokine recepter-4 mediates the secretion of
matrix metalloproteinases from mouse hepatocarcinoma cell lines
with different lymphatic metastasis ability. Int J Biochem Cell
Biol. 39:197–205. 2007.
|
|
9
|
Tang J, Zhang L, She X, et al: Inhibiting
CD164 expression in colon cancer cell line HCT116 leads to reduced
cancer cell proliferation, mobility, and metastasis in vitro
and in vivo. Cancer Invest. 30:380–389. 2012.
|
|
10
|
David NB, Sapède D, Saint-Etienne L, et
al: Molecular basis of cell migration in the fish lateral line:
role of the chemokine receptor CXCR4 and of its ligand, SDF1. Proc
Natl Acad Sci USA. 99:16297–16302. 2002.
|
|
11
|
Babcock GJ, Farzan M and Sodroski J:
Ligand-independent dimerization of CXCR4, a principal HIV-1
coreceptor. J Biol Chem. 278:3378–3385. 2003.
|
|
12
|
Sun YX, Wang J, Shelburne CE, et al:
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers
(PCa) in vivo. J Cell Biochem. 89:462–473. 2003.
|
|
13
|
Phillips RJ, Burdick MD, Lutz M, et al:
The stromal derived factor-1/CXCL12-CXC chemokine receptor 4
biological axis in non-small cell lung cancer metastases. Am J
Respir Crit Care Med. 167:1676–1686. 2003.
|
|
14
|
Koshiba T, Hosotani R, Miyamoto Y, et al:
Expression of stromal cell-derived factor 1 and CXCR4 ligand
receptor system in pancreatic cancer: a possible role for tumor
progression. Clin Cancer Res. 6:3530–3535. 2000.
|
|
15
|
Raman D, Baugher PJ, Thu YM and Richmond
A: Role of chemokines in tumor growth. Cancer Lett. 256:137–165.
2007.
|
|
16
|
Sun YX, Fang M, Wang J, et al: Expression
and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases
the aggressiveness of prostate cancer cells. Prostate. 67:61–73.
2007.
|
|
17
|
Sutton A, Friand V, Brulé-Donneger S, et
al: Stromal cell-derived factor-1/chemokine (CXC motif) ligand 12
stimulates human hepatoma cell growth, migration, and invasion. Mol
Cancer Res. 5:21–33. 2007.
|
|
18
|
Smith MC, Luker KE, Garbow JR, et al:
CXCR4 regulates growth of both primary and metastatic breast
cancer. Cancer Res. 64:8604–8612. 2004.
|
|
19
|
Hannon GJ: RNA interference. Nature.
418:244–251. 2002.
|
|
20
|
Elbashir SM, Lendeckel W and Tuschl T: RNA
interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev.
15:188–200. 2001.
|
|
21
|
Aravin AA, Klenov MS, Vagin VV, Rozovskiĭ
IaM and Gvozdev VA: Role of double-stranded RNA in eukaryotic gene
silencing. Mol Biol (Mosk). 36:240–251. 2002.(In Russian).
|
|
22
|
Sanguino A, Lopez-Berestein G and Sood AK:
Strategies for in vivo siRNA delivery in cancer. Mini Rev
Med Chem. 8:248–255. 2008.
|
|
23
|
Lapteva N, Yang AG, Sanders DE, Strube RW
and Chen SY: CXCR4 knockdown by small interfering RNA abrogates
breast tumor growth in vivo. Cancer Gene Ther. 12:84–89.
2005.
|
|
24
|
Ueda Y, Neel NF, Schutyser E, Raman D and
Richmond A: Deletion of the COOH-terminal domain of CXC chemokine
receptor 4 leads to the down-regulation of cell-to-cell contact,
enhanced motility and proliferation in breast carcinoma cells.
Cancer Res. 66:5665–5675. 2006.
|
|
25
|
Yoon Y, Liang Z, Zhang X, et al: CXC
chemokine receptor-4 antagonist blocks both growth of primary tumor
and metastasis of head and neck cancer in xenograft mouse models.
Cancer Res. 67:7518–7524. 2007.
|
|
26
|
Zeelenberg IS, Ruuls-Van Stalle L and Roos
E: The chemokine receptor CXCR4 is required for outgrowth of colon
carcinoma micrometastases. Cancer Res. 63:3833–3839. 2003.
|
|
27
|
Huang EH, Singh B, Cristofanilli M, et al:
A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and
metastasis of breast cancer. J Surg Res. 155:231–236. 2009.
|
|
28
|
Richert MM, Vaidya KS, Mills CN, et al:
Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis
to lung and bone. Oncol Rep. 21:761–767. 2009.
|
